Floatz logo

Vinpocetine

Stroke

Tianjin Medical University General HospitalSmall moleculePhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
65/ 100

Competitive context

133 Active assets in the Stroke cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
Aggrenox
Boehringer Ingelheim
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB

View all 50 →

Same molecule, other indications

Vinpocetine is also rated in:

ImmunoregulationDormant
B
Indicative ·
61 / 100
View asset →
VinpocetineDormant
B
Indicative ·
61 / 100
View asset →
inflammatory diseaseDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →